WO2001019399A3 - Method of potentiating chemotherapy and treating solid tumors - Google Patents

Method of potentiating chemotherapy and treating solid tumors Download PDF

Info

Publication number
WO2001019399A3
WO2001019399A3 PCT/US2000/025008 US0025008W WO0119399A3 WO 2001019399 A3 WO2001019399 A3 WO 2001019399A3 US 0025008 W US0025008 W US 0025008W WO 0119399 A3 WO0119399 A3 WO 0119399A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid tumors
treating solid
potentiating
regimen
chemotherapy
Prior art date
Application number
PCT/US2000/025008
Other languages
French (fr)
Other versions
WO2001019399A2 (en
Inventor
James Joseph Gibbons Jr
Gary Dukart
Judy Lucas
Lisa Anne Speicher
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Priority to CA002381078A priority Critical patent/CA2381078A1/en
Priority to EP00961841A priority patent/EP1214092A2/en
Priority to BR0014001-5A priority patent/BR0014001A/en
Priority to JP2001523030A priority patent/JP2003509383A/en
Priority to AU73736/00A priority patent/AU7373600A/en
Publication of WO2001019399A2 publication Critical patent/WO2001019399A2/en
Publication of WO2001019399A3 publication Critical patent/WO2001019399A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention provides a method of treating solid tumors which comprises administering an effective amount of a combination of (1) a bioresponse modifier and (2) a chemotherapeutic agent. This invention also provides a method of potentiating the effects of a chemotherapeutic regimen in a mammal in need of treatment with such regimen which comprises administering a bioresponse modifier in addition to a chemotherapeutic regimen.
PCT/US2000/025008 1999-09-15 2000-09-12 Method of potentiating chemotherapy and treating solid tumors WO2001019399A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002381078A CA2381078A1 (en) 1999-09-15 2000-09-12 Method of potentiating chemotherapy and treating solid tumors
EP00961841A EP1214092A2 (en) 1999-09-15 2000-09-12 Method of potentiating chemotherapy and treating solid tumors
BR0014001-5A BR0014001A (en) 1999-09-15 2000-09-12 Chemotherapy potentiation method and treatment of solid tumors
JP2001523030A JP2003509383A (en) 1999-09-15 2000-09-12 How to enhance chemotherapy and treat solid tumors
AU73736/00A AU7373600A (en) 1999-09-15 2000-09-12 Method of potentiating chemotherapy and treating solid tumors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39605199A 1999-09-15 1999-09-15
US09/396,051 1999-09-15

Publications (2)

Publication Number Publication Date
WO2001019399A2 WO2001019399A2 (en) 2001-03-22
WO2001019399A3 true WO2001019399A3 (en) 2001-12-13

Family

ID=23565645

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/025008 WO2001019399A2 (en) 1999-09-15 2000-09-12 Method of potentiating chemotherapy and treating solid tumors

Country Status (8)

Country Link
EP (1) EP1214092A2 (en)
JP (1) JP2003509383A (en)
CN (1) CN1391484A (en)
AR (1) AR025659A1 (en)
AU (1) AU7373600A (en)
BR (1) BR0014001A (en)
CA (1) CA2381078A1 (en)
WO (1) WO2001019399A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299756B6 (en) * 2001-05-16 2008-11-12 Novartis Ag Combination containing N-(5-[4-(4-methyl-piperazino-methyl)benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine intended for the treatment of proliferative diseases
CN109601739B (en) * 2019-01-17 2022-10-14 河南湾流生物科技有限公司 Compound amino acid feed additive and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042099A1 (en) * 1998-02-24 1999-08-26 Dovetail Technologies Inc. Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof
WO2000038665A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042099A1 (en) * 1998-02-24 1999-08-26 Dovetail Technologies Inc. Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof
WO2000038665A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P.KIER: "high-dose chemotherapy and autologous stem-cell transplantation in breast cancer", ACTA MEDICA AUSTRIACA, vol. 27, no. suppl.52, 2000, pages 33 - 36, XP001009709 *

Also Published As

Publication number Publication date
BR0014001A (en) 2002-05-21
AU7373600A (en) 2001-04-17
AR025659A1 (en) 2002-12-11
WO2001019399A2 (en) 2001-03-22
CN1391484A (en) 2003-01-15
CA2381078A1 (en) 2001-03-22
EP1214092A2 (en) 2002-06-19
JP2003509383A (en) 2003-03-11

Similar Documents

Publication Publication Date Title
EP1314431A3 (en) Newcastle disease virus for therapeutic use
CA2255615A1 (en) Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
HK1022301A1 (en) Conjugates of cisdocosahexaenoic acid and paclitaxel
BR0207378A (en) Cancer treatment
EP1355563A4 (en) METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES
CA2380904A1 (en) Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
HK1049787A1 (en) Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2000038665A3 (en) Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CA2163904A1 (en) Use of Indolocarbazole Derivatives to Treat a Pathological Condition of the Prostate
EP0926955A4 (en) Conjugates useful in the treatment of prostate cancer
IL129356A0 (en) Conjugates useful in the treatment of prostate cancer
HUP0104688A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
IL141686A0 (en) Methods of treating hypertension and compositions for use therein
WO1997005872A3 (en) Use of 1h-1,2,4-triazole derivatives for inhibiting the growth of cancers
ZA954984B (en) Compositions and methods for the treatment of tumors
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
WO2001019399A3 (en) Method of potentiating chemotherapy and treating solid tumors
EP1003516A4 (en) Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
AU2196297A (en) Methods of treating or preventing interstitial cystitis
WO2001034131A3 (en) Combination chemotherapy
WO1999021574A3 (en) Enhancement of morphogen activity
EP1073436A4 (en) IMPROVED METHOD FOR ERADICATION OF $i(HELICOBACTER PYLORI)
IL143012A0 (en) Pharmaceutical composition comprising an anti-cancer agent and at least one peptide
IL120495A0 (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
EP1259255A4 (en) Pai-2 conjugates for the treatment and imaging of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000961841

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 523030

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2381078

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 008129215

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000961841

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000961841

Country of ref document: EP